fbpx

ArriVent’s Nasdaq Debut Nabs $175M As Signs Indicate An Opening IPO Window

ArriVent BioPharma will apply the IPO cash toward furmonertinib, which the biotech says could offer advantages over Takeda Pharmaceutical and Johnson & Johnson drugs that address the same lung cancer target. It’s the second biotech IPO of this week, following CG Oncology.

The post ArriVent’s Nasdaq Debut Nabs $175M As Signs Indicate An Opening IPO Window appeared first on Above the Law.

Related Articles

Responses

Your email address will not be published. Required fields are marked *